Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
AZ703 proposed as novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor
June 2nd, 2006
AZ703 was proposed as a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase (CDK) inhibitor. According to recent research published in the journal Molecular Cancer Therapeutics, "Because the majority of cancers exhibit direct or indirect deregulation of CDK function, members of the CDK family are attractive targets for the development of anticancer agents. As part of an ongoing program, novel imidazopyridines were identified and developed as potent and selective CDK inhibitors." "Here, we describe data on the in vitro biological activities of one of these compounds, AZ703," explained K.F. Byth and colleagues, AstraZeneca R&D Boston....
Source: Medicine & Law Weekly (2006-06-02)
|
